Mar 1, 2011
By:
William Looney
Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
|
|
Feb 4, 2011
By:
William Looney
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
|
|
Feb 1, 2011
By:
William Looney
What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
|
|
Jan 1, 2011
By:
William Looney
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
|
|
Jan 1, 2011
By:
William Looney
Building the commercial and policy base for effective collaboration in biotech
|
Dec 1, 2010
By:
William Looney
The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica
|
|
Dec 1, 2010
By:
William Looney
Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office
|
Dec 1, 2010
By:
William Looney
Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend
|
|
Dec 1, 2010
By:
William Looney
The end of anther year is an appropriate time to highlight the march of time—and the transitions that accompany it
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
